Table 4.
Hazard ratios for EMLgenome/EMLPD measures and time to event - (having a score of 35+ on mUPDRS) and time to death in PD patients
| Outcome | Stratum | EML scoring criterion | Hazard Ratio (95% CI) | p |
|---|---|---|---|---|
| mUPDRS 35 | All (n = 455) | genome | 1.28 (1.06–1.56) | 0.011 |
| PD-genes | 1.30 (1.08–1.56) | 0.062 | ||
| Female (n = 165) | genome | 1.43 (1.10–1.86) | 7.7e-3 | |
| PD-genes | 1.41 (1.09–1.82) | 8.0e-3 | ||
| Male (n = 290) | genome | 1.06 (0.79–1.43) | 0.69 | |
| PD-genes | 1.11 (0.83–1.48) | 0.50 | ||
| Time to death | All (n = 357) | genome | 1.29 (1.11–1.49) | 6.9e-4 |
| PD-genes | 1.29 (1.12–1.48) | 3.6e-4 | ||
| Female (n = 138) | genome | 1.33 (1.07–1.64) | 9.1e-3 | |
| PD-genes | 1.31 (1.07–1.60) | 0.088 | ||
| Male (n = 165) | genome | 1.16 (0.94–1.45) | 0.17 | |
| PD-genes | 1.21 (0.97–1.49) | 0.088 |
Models control for sex, age, ethnicity, cell counts (Gran, NK, CD8pCD28nCD45RAn, CD4T), total levodopa equivalent (total_led), PRS (polygenic risk score), and PD duration in years.